Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies01:28

Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies

497
Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
497
Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules01:18

Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules

255
Bioequivalence in generic drugs, such as tablets and capsules, refers to their pharmaceutical equivalence to the brand-name counterparts. However, for therapeutic equivalence, manufacturers must also consider physical attributes like size, shape, and weight (FDA Guidance for Industry, December 2003). Discrepancies in these aspects could impact patient compliance and cause medication errors. For instance, swallowing difficulties, often experienced with larger tablets or capsules, can lead to...
255
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents01:24

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

1.3K
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
1.3K
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

1.0K
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
1.0K
Clinically Relevant Drug Product Specifications: Methods of Establishment01:29

Clinically Relevant Drug Product Specifications: Methods of Establishment

171
Product specifications define the acceptable quality of a pharmaceutical product by ensuring identity, purity, potency, and strength. These specifications serve as benchmarks during development, manufacturing, and post-approval quality control. Clinically relevant specifications are particularly important because they directly relate to a drug's safety and efficacy in clinical use.Dissolution studies are critical biopharmaceutic tools that link in vitro behavior to in vivo performance. They...
171
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

392
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
392

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Moxibustion Alleviates Inflammation via SIRT5-mediated Post-translational Modification and Macrophage Polarization.

Inflammation·2025
Same author

Five-year complete remission of super-giant hepatocellular carcinoma with hepatectomy followed by sorafenib plus camrelizumab: A case report.

World journal of gastrointestinal surgery·2025
Same author

Role of SIRT5 in the analgesic effectiveness of moxibustion at ST36 in mice with inflammatory pain.

Heliyon·2023
Same author

Effects of Chinese Medicine on Symptoms, Syndrome Evolution, and Lung Inflammation Absorption in COVID-19 Convalescent Patients during 84-Day Follow-up after Hospital Discharge: A Prospective Cohort and Nested Case-Control Study.

Chinese journal of integrative medicine·2021
Same author

[Light and heat of moxibustion for knee osteoarthritis：a multi-center randomized controlled trial].

Zhongguo zhen jiu = Chinese acupuncture & moxibustion·2020
Same author

Decreased human leukocyte antigen A*02:01 frequency is associated with risk of glioma and existence of human cytomegalovirus: a case-control study in Northern China.

Cancer immunology, immunotherapy : CII·2017
Same journal

[Research status and comprehensive evaluation strategies for quality uniformity of Chinese patent medicines].

Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica·2026
Same journal

[Clinical research evidence map analysis of TCM in treatment of unstable angina pectoris in elderly patients].

Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica·2026
Same journal

[Diagnostic criteria for kidney Yang deficiency syndrome in male infertility].

Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica·2026
Same journal

[Study on metabolism and excretion of Yanlishuang Oral Dripping Pills in rat bile, feces, and urine based on chromatography-mass spectrometry technology].

Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica·2026
Same journal

[Effect and mechanism of Ligustrum robustum extract in intervening in lipid metabolism pathways to reduce lipid levels in hyperlipidemic mice].

Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica·2026
Same journal

[Metabolomics and metagenomics reveal mechanism of Xinglou Chengqi Decoction in preventing cerebral ischemia-reperfusion injury].

Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica·2026
See all related articles

Related Experiment Video

Updated: Jan 5, 2026

Formation of Dispersible Taohong Siwu Tablets
05:44

Formation of Dispersible Taohong Siwu Tablets

Published on: February 3, 2023

2.0K

[Expert consensus statement on Hugan Tablets in clinical practice].

Huan Liu1, Rong-Bing Wang2, Yan-Ming Xie1

  • 1Institute of Basic Research in Clinical Medicine,China Academy of Chinese Medical Sciences Beijing 100700,China.

Zhongguo Zhong Yao Za Zhi = Zhongguo Zhongyao Zazhi = China Journal of Chinese Materia Medica
|October 12, 2019
PubMed
Summary
This summary is machine-generated.

This expert consensus provides guidance on using Hugan Tablets, a Chinese patent medicine for anti-inflammation and reducing transaminase levels. It standardizes clinical application to enhance efficacy and safety based on evidence and expert opinion.

Keywords:
Chinese medicineChinese patent drugHugan Tabletsevidence-based medicineexpert consensus

More Related Videos

Meta-Analysis of the Effectiveness and Safety of Shugan Jieyu Capsules for the Treatment of Insomnia
04:34

Meta-Analysis of the Effectiveness and Safety of Shugan Jieyu Capsules for the Treatment of Insomnia

Published on: February 17, 2023

1.5K
Preparation Of Gushukang GSK Granules for In Vivo and In Vitro Experiments
06:16

Preparation Of Gushukang GSK Granules for In Vivo and In Vitro Experiments

Published on: May 9, 2019

8.0K

Related Experiment Videos

Last Updated: Jan 5, 2026

Formation of Dispersible Taohong Siwu Tablets
05:44

Formation of Dispersible Taohong Siwu Tablets

Published on: February 3, 2023

2.0K
Meta-Analysis of the Effectiveness and Safety of Shugan Jieyu Capsules for the Treatment of Insomnia
04:34

Meta-Analysis of the Effectiveness and Safety of Shugan Jieyu Capsules for the Treatment of Insomnia

Published on: February 17, 2023

1.5K
Preparation Of Gushukang GSK Granules for In Vivo and In Vitro Experiments
06:16

Preparation Of Gushukang GSK Granules for In Vivo and In Vitro Experiments

Published on: May 9, 2019

8.0K

Area of Science:

  • Pharmacology and Therapeutics
  • Evidence-Based Medicine
  • Clinical Practice Guidelines

Background:

  • Hugan Tablets is a Chinese patent medicine known for anti-inflammatory properties and reducing transaminase levels.
  • Current clinical use lacks standardized guidelines, necessitating expert consensus for optimal application.

Purpose of the Study:

  • To develop an expert consensus statement for the rational clinical use of Hugan Tablets.
  • To guide and standardize therapeutic strategies, improving treatment efficacy and patient safety.

Main Methods:

  • Systematic literature review and expert questionnaire investigation.
  • Application of international clinical practice guideline development methods, including GRADE criteria.
  • Nominal group technique employed for expert consensus formation.

Main Results:

  • Two recommendations and eight consensus opinions were formulated, focusing on indications, dosage, special populations, and safety.
  • The consensus considered evidence quality, efficacy, safety, cost-effectiveness, and patient acceptability.

Conclusions:

  • The developed expert consensus provides a standardized framework for clinicians regarding Hugan Tablets.
  • This guidance aims to ensure rational drug use, optimize clinical outcomes, and enhance patient safety in diverse healthcare settings.